|NASDAQ: ELVN||Healthcare / Biotechnology / USA|
|19.71||-4.04||-17.01%||Vol 2.15K||1Y Perf -|
|Feb 27th, 2023 09:30 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||Moderate Buy 1.67|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||0.00||Earnings Rating||—|
|Market Cap||810.08M||Earnings Date||5th May 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2023|
|Estimated EPS Next Report||-0.81|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||0|
|Avg. Monthly Volume||0|
|Avg. Quarterly Volume||0|
Enliven Therapeutics Inc Com (NASDAQ: ELVN) stock closed at 23.49 per share at the end of the most recent trading day (a -17.01% change compared to the prior day closing price) with a volume of 2.15K shares and market capitalization of 810.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Enliven Therapeutics Inc Com CEO is Sam Kintz.
The one-year performance of Enliven Therapeutics Inc Com stock is %, while year-to-date (YTD) performance is 20.48%. ELVN stock has a five-year performance of %. Its 52-week range is between 3.8956 and 25.34, which gives ELVN stock a 52-week price range ratio of %
Enliven Therapeutics Inc Com currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -%, a ROC of -% and a ROE of -%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.
Of the last four earnings reports from Enliven Therapeutics Inc Com, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.81 for the next earnings report. Enliven Therapeutics Inc Com’s next earnings report date is 05th May 2023.
The consensus rating of Wall Street analysts for Enliven Therapeutics Inc Com is Moderate Buy (1.67), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Enliven Therapeutics Inc Com stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enliven Therapeutics Inc Com has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enliven Therapeutics Inc Com has a Buy technical analysis rating based on Technical Indicators (ADX : 20.03, ATR14 : 2.11, CCI20 : 37.06, Chaikin Money Flow : 0.40, MACD : 3.56, Money Flow Index : 53.01, ROC : -0.57, RSI : 49.25, STOCH (14,3) : 42.44, UO : 66.92, Williams %R : -57.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enliven Therapeutics Inc Com in the last 12-months were: Michael P. Gray (Sold 3 596 shares of value $14 096 ), Rahul D. Ballal (Sold 11 313 shares of value $44 234 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Hold||Hold|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
CEO: Sam Kintz
Telephone: +1 720 647-8519
Address: 6200 Lookout Road, Boulder 80301, CO, US
Number of employees: 0
Tue, 07 Mar 2023 13:05 GMT Enliven Therapeutics (ELVN) Initiated with a Buy at LifeSci Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.